Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Adv Exp Med Biol. 2021;1322:115–138. doi: 10.1007/978-981-16-0267-2_5

Table 5.7.

STOPs (s-antigen transport inhibiting oligonucleotide polymers) in development

Drug EC50 μM Route Company Clinical trial phase ClinicalTrials.gov identifier
ALG-10133 0.0032 Parenteral (SC) Aligos Therapeutics, USA 1 NCT04485663

EC50 median effective concentration to inhibit HBV DNA replication